Bolt Biotherapeutics, Inc. (BOLT) Bundle
Who Invests in Bolt Biotherapeutics, Inc. (BOLT) and Why?
Investor Profile Analysis for Emerging Biotechnology Company
Key Investor Types
| Investor Category | Percentage of Ownership | Investment Amount |
|---|---|---|
| Institutional Investors | 68.5% | $124.3 million |
| Mutual Funds | 22.7% | $41.6 million |
| Retail Investors | 8.8% | $16.1 million |
Institutional Investor Breakdown
- BlackRock: 7.2% ownership
- Vanguard Group: 6.5% ownership
- Dimensional Fund Advisors: 4.3% ownership
Investment Motivations
Investors attracted by:
- Potential breakthrough therapeutic technologies
- Strong research pipeline
- Market capitalization of $287 million
- Cash reserves of $156.4 million as of Q4 2023
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62.3% |
| Growth Investing | 24.6% |
| Short-term Trading | 13.1% |
Investor Risk Profile
Average investor risk tolerance: Moderate to High
- Average investment duration: 2-3 years
- Typical investment range: $50,000 - $500,000
Institutional Ownership and Major Shareholders of Bolt Biotherapeutics, Inc. (BOLT)
Investor Profile Analysis for Emerging Biotechnology Company
Key Investor Types
| Investor Category | Percentage of Ownership | Investment Amount |
|---|---|---|
| Institutional Investors | 68.5% | $124.3 million |
| Mutual Funds | 22.7% | $41.6 million |
| Retail Investors | 8.8% | $16.1 million |
Institutional Investor Breakdown
- BlackRock: 7.2% ownership
- Vanguard Group: 6.5% ownership
- Dimensional Fund Advisors: 4.3% ownership
Investment Motivations
Investors attracted by:
- Potential breakthrough therapeutic technologies
- Strong research pipeline
- Market capitalization of $287 million
- Cash reserves of $156.4 million as of Q4 2023
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62.3% |
| Growth Investing | 24.6% |
| Short-term Trading | 13.1% |
Investor Risk Profile
Average investor risk tolerance: Moderate to High
- Average investment duration: 2-3 years
- Typical investment range: $50,000 - $500,000
Key Investors and Their Influence on Bolt Biotherapeutics, Inc. (BOLT)
Institutional Ownership and Major Shareholders Analysis
As of the latest available data, institutional investors hold 89.7% of the total outstanding shares for the company.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Baker Bros. Advisors LP | 4,562,739 | 16.4% |
| Fidelity Management & Research | 3,215,682 | 11.5% |
| Citadel Advisors LLC | 2,874,531 | 10.3% |
| Vanguard Group Inc | 2,456,789 | 8.8% |
Institutional Ownership Changes
Recent quarterly data indicates significant ownership dynamics:
- Total institutional investors increased from 87.3% to 89.7%
- 14 new institutional investors entered the position
- 22 existing institutional investors increased their stakes
- 9 institutional investors reduced their holdings
Ownership Concentration
The top 5 institutional investors control approximately 47% of total outstanding shares, demonstrating significant concentrated ownership.
Ownership Metrics
| Metric | Value |
|---|---|
| Total Institutional Investors | 287 |
| Institutional Ownership Percentage | 89.7% |
| Shares Outstanding | 27,943,521 |
Market Impact and Investor Sentiment of Bolt Biotherapeutics, Inc. (BOLT)
Key Investors and Their Strategic Holdings
As of Q4 2023, the investor landscape for the company reveals significant institutional involvement and strategic positioning.
| Investor Category | Ownership Percentage | Shares Held |
|---|---|---|
| Institutional Investors | 78.3% | 14,672,000 shares |
| Vanguard Group Inc | 12.4% | 2,331,456 shares |
| BlackRock Inc | 9.7% | 1,822,300 shares |
Notable Institutional Investors
- Vanguard Group Inc: $2.3 million total investment
- BlackRock Inc: $1.8 million total investment
- Fidelity Management & Research: $1.2 million total investment
Investor Movement Insights
Recent SEC filings indicate significant investor activity during 2023:
- Total institutional investor transactions: 47 reported trades
- Net buying volume: 1,240,000 shares
- Average transaction size: 26,500 shares
Investor Profile Breakdown
| Investor Type | Percentage | Average Investment |
|---|---|---|
| Hedge Funds | 34.6% | $750,000 |
| Mutual Funds | 25.3% | $450,000 |
| Individual Investors | 12.1% | $85,000 |
Bolt Biotherapeutics, Inc. (BOLT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.